Kevin Dat Vuong, M.A.

Instructor of Neurology

Graduate School

M.A. (1997) Binghamton University, New York

Clinical Interests

Movement disorders including Parkinson's disease, essential tremor, dystonia, Tourette's syndrome and Huntington's disease

Research Interests

Statistical analysis, database management and psychometrics in assessing the various components of movement disorders

Publications
Collapse All | Expand All

Ondo WG, Meilak C, Vuong KD. Predictors of battery life for the Activa Soletra 7426 Neurostimulator. Parkinsonism Relat Disord 2007;13:240-2.
Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr 2006;11:501-8.
Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord 2006;12:382-7.
Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005;20:592-7.
Ondo WG, Wang A, Thomas M, Vuong KD. Evaluating factors that can influence spirography ratings in patients with essential tremor. Parkinsonism Relat Disord 2005;11:45-8.
Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J 2005;20:44-7.
Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics 2004;114:1203-5.
Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61:1393-7.
Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004;27:274-7.
Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004;24:60-5.
Thomas M, Jankovic J, Suteerawattananon M, Wankadia S, Caroline KS, Vuong KD, Protas E. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci 2004;217:89-99.
Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord 2003;18:1190-2.
Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-8.
Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol 2003;60:1595-8.
Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-5.
Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002;59:421-4.
Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000;15:678-82.
Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord 2000;6:237-240.
Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000;55:1404-6.

Poster Presentations
View Details | Collapse All | Expand All

Sitburana O, Rountree S, Vuong KD, Ondo W. Weight change in parkinson and alzheimer patients taking atypical antipsychotic drugs. Mov Disord. 2007:22 Suppl 16:S190.
Diamond AL, Vuong KD, Jankovic J. Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life. Ann Neurol. 2006;60 Suppl 10:S77.
Diamond AL, Vuong KD, Jankovic J. Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life. Mov Disord. 2006;21 Suppl 15:S669.
Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J. Long term safety of deep brain stimulation for the treatment of Parkinson's disease. Neurology. 2006;66(5 Suppl 2):A49-50.
Azher SN, Vuong KD, Shahed J, Diamond AL, Jankovic J. Gait and balance assessment in parkinsonian disorders. Mov Disord. 2005:20 Suppl 10:S112-3.
Diamond AL, Shahed J, Azher SN, Vuong KD, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2005:20 Suppl 10:S153-4.
Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine: Does prior history of depression preclude this drug as a treatment option? Mov Disord. 2005:20 Suppl 10:S47.
Mejia N, Vuong KD, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia. Mov Disord. 2005:20 Suppl 10:S18.
Ondo WG, Meilak C, Vuong KD, Jankovic J. Predictors of battery life for the Activa® Soletra 7426 neurostimulator. Mov Disord. 2005:20 Suppl 10:S160-1.
Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Mov Disord. 2005:20 Suppl 10:S169-70.
Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Neurology. 2005;64(6 Suppl 1):A255.
Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome. Mov Disord. 2004:19 Suppl 9:S437.
Hunter CB, Vuong KD, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology. 2004:62(7 Suppl S5):A506-7.
Jankovic J, Hunter C, Mejia N, Vuong KD. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov Disord. 2004:19 Suppl 9:S73.
Jankovic J, Hunter CB, Vuong KD. Tetrabenazine in the treatment of chorea. American Society for Experimental NeuroTherapeutics (ASENT), 6th Annual Meeting in Bethesda, Maryland (March 11-13, 2004).
Jankovic J, Hunter CB, Vuong KD. Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas. Mov Disord. 2004:19(9):1127.
Jankovic J, Madisetty J, Vuong KD. Essential tremor in children. Neurology. 2004:62(7 Suppl S5):A502.
Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: Long-term outcome. Neurology. 2004:62(7 Suppl S5):A501.
Silay Y, Jankovic J, Vuong KD, Almageur M, Ondo WG, Tintner R, Simpson Jr RK. The safety of deep brain stimulation in patients with Parkinson's disease, essential tremor, and other movement disorders. Ann Neurol. 2004;56 Suppl 8:S54-5.
Silay YS, Vuong KD, Jankovic J. The efficacy and safety of fluphenazine in patients with Tourette syndrome. Neurology. 2004:62(7 Suppl S5):A506.
Silver GA, Vuong KD, Jankovic J. Young-onset versus late-onset Parkinson's disease: Clinical features and disease progression. Mov Disord. 2004:19 Suppl 9:S264.
Thomas M, Banuelos P, Vuong KD, Jankovic J. Long-term prognosis of psychogenic movement disorders. Mov Disord. 2004:19 Suppl 9:S431.
Thomas M, Vuong KD, Jankovic J. Psychogenic dystonia: Clinical characteristics and long-term progression. Mov Disord. 2004:19 Suppl 9:S111.
Vuong KD, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov Disord. 2004:19 Suppl 9:S422.
Ondo WG, Romanyshyn J, Vuong KD. Long term treatment of restless legs syndrome with dopamine agonists. Neurology. 2003;60(5 Suppl 1):A291.
Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal fold augmentation in patients with parkinsonism. Mov Disord. 2002:17 Suppl 5:S105.
Hunter CB, Wang A, Vuong KD, Jankovic J. Age-related tolerability of tetrabenazine. Mov Disord. 2002:17 Suppl 5:S41.
Hunter CB, Wang A, Vuong KD, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. Mov Disord. 2002:17 Suppl 5:S341.
Jankovic J, Ahsan J, Vuong KD. Comparison of immunogenicity of old versus current Botox in cervical dystonia. Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, International Conference in Hannover, Germany (June 8, 2002).
Ondo WG, Vuong KD, Derman HS. Botulinum toxin A (Botox) for chronic daily headache: A randomized placebo-controlled, parallel design study. Headache. 2002;42(5):414.
Ondo WG, Wang A, Thomas M, Vuong KD. Evaluating factors that can influence spirography ratings in patients with essential tremor. Mov Disord. 2002:17 Suppl 5:S344.
Tintner R, Almaguer M, Vuong KD, Ondo WG, Jankovic J, Sanghera M. Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord. 2002:17 Suppl 5:S208.
Atassi F, Vuong KD, Jankovic J, Ondo WG. The prevalence of restless legs syndrome in patients with Parkinson's disease. Neurology. 2001;56(8 Suppl 3):A21.
Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson's disease and restless legs syndrome. Neurology. 2001;56(8 Suppl 3).
Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine treatment for dopaminergic induced hallucinations. Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).
Ondo WG, Vuong KD, Atassi F, Khan H, Kwak C, Jankovic J. Daytime sleepiness in patients with Parkinson's disease. Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).
Vuong KD, Ondo WnG, Almaguer M, Simpson RK, Jankovic J. Unilateral thalamic deep brain stimulation for essential tremor and Parkinson's disease: Effects of stimulation on the non-target limb and rebound augmentation. Neurology. 2000;54(Suppl 3):A54.

Contact Information

Kevin Dat Vuong, M.A.
Manager, Information Technology
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-5427
Fax: 713-798-3853
Email: